Changes of Plasma Tumor Necrosis Factor α and C-Reactive Protein Levels in Patients with Hypertension Accompanied by Impaired Glucose Tolerance and their Clinical Significance

  • Xiao, Qiang (Department of Cardiovascular Medicine, Affiliated Hospital of Taishan Medical University) ;
  • Wang, Lan-Ping (Operation Room of Cardiovascular Surgery, Affiliated Hospital of Taishan Medical University) ;
  • Ran, Zhang-Shen (The Center for Cadre Health Care and Physical Examination, Affiliated Hospital of Taishan Medical University) ;
  • Zhang, Xin-Huan (Department of Endocrinology, Affiliated Hospital of Taishan Medical University)
  • Published : 2015.04.29


Background: Chronic inflammation could affect the occurrence and development of malignant tumors. To explore the levels of tumor necrosis factor ${\alpha}$ (TNF-${\alpha}$) and C-reactive protein (CRP) in patients accompanied by impaired glucose tolerance (IGT) and their clinical significance. Materials and Methods: A total of 210 patients hospitalized in Affiliated Hospital of Taishan Medical University from Jun., 2013 to Dec., 2014 were selected, in which 92 cases were accompanied by IGT. Meanwhile, 80 randomly-selected healthy people by physical examination were as the control. The levels of routine biochemical indexes, plasma TNF-${\alpha}$ and CRP in all subjects were measured. Results: Both systolic and diastolic pressures in hypertension group and hypertension plus IGT group were significantly higher than in control group (p<0.01), but there was no statistical significance between these two groups (p>0.05). The levels of fasting plasma glucose (FPG) and blood glucose 2 h after taking glucose in hypertension plus IGT group were markedly higher than other groups (p<0.01). Homeostasis model assessment-insulin resistance (HOMA-IR), TNF-${\alpha}$ and CRP contents were on the progressive increase in control, hypertension and hypertension plus IGT groups, but significant differences were presented among each group (P<0.01). Hypertension accompanied by IGT had a significantly-positive association with CRP, TNF-${\alpha}$, FPG and blood glucose 2h after taking glucose. Conclusions: The levels of plasma TNF-${\alpha}$ and CPR in patients with hypertension accompanied by IGT increase significantly, indicating that inflammatory reaction in these patient increases, thus suggesting that these patients should be focused regarding cancer prevention.


  1. Akande TO, Adeleye JO, Kadiri S, et al (2013). Insulin resistance in Nigerians with essential hypertension. Afr Health Sci, 13, 655-60.
  2. Bautista LE1, Vera LM, Arenas IA, et al (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens, 19, 149-54.
  3. Chang EJ, Lee SK, Song YS, et al (2014). IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab, 99, 1263-71.
  4. Charles KA, Kulbe H, Soper R, et al (2009). The tumorpromoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest, 119, 3011-23.
  5. Chen YS, Xu SX, Ding YB, et al (2014). Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev, 14, 6487-91.
  6. Chen YS, Xu SX, Ding YB, et al (2013). Helicobacter pylori infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev, 14, 7613-9.
  7. Cuspidi C, Rescaldani M, Tadic M, et al (2015). White-coat hypertension, as defined by ambulatory blood pressure monitoring and subclinical cardiac organ damage: a metaanalysis. J Hypertens, 33, 24-32.
  8. Daniele G, Guardado Mendoza R, Winnier D, et al (2013). The inflammatory status score including IL-6, TNF-$\alpha$, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol, 51, 123-31.
  9. Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al (2009). Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw, 20, 131-4.
  10. Hage FG (2014). C-reactive protein and Hypertension. J Hum Hypertens, 28, 410-5.
  11. Hashimoto K, Ikeda Y, Korenaga D, et al(2005). The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer, 103, 1856-64.
  12. Hefler LA, Concin N, Hofstetter G, et al(2008). Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res, 14, 710-4.
  13. Hellgren MI, Daka B, Jansson PA, et al (2014). Primary care screening for individuals with impaired glucose metabolism with focus on impaired glucose tolerance. Prim Care Diabetes, doi: 10.1016/j.pcd.2014.10.009.
  14. Herishanu Y, Perry C, Braunstein R, et al (2007). Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Haematol, 79, 150-4.
  15. Karakiewicz PI, Hutterer GC, Trinh QD, et al (2007). C-reactive protein is an informative predictor of renal cell carcinomaspecific mortality: a European study of 313 patients. Cancer, 110, 1241-7.
  16. Koike Y, Miki C, Okugawa Y, et al(2008). Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol, 98, 540-4.
  17. Lee SJ, Kim WJ, Moon SK (2009). TNF-alpha regulates vascular smooth muscle cell responses in genetic hypertension. Int Immunopharmacol, 9, 837-43.
  18. Mantovani A (2009). Cancer: Inflaming metastasis. Nature, 457, 36-7.
  19. Mauer J, Chaurasia B, Goldau J, et al (2014). Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol, 15, 423-30.
  20. Obuchowicz A, Kniażewska M, Zmudzinska-Kitczak J, et al (2014). Concentrations of tumour necrosis factor-$\alpha$ and its soluble receptors in the serum of teenagers with atherosclerosis risk factors: obesity or obesity combined with hypertension. J Pediatr Endocrinol Metab, 27, 1209-12.
  21. Pine JK, Fusai KG, Young R, et al (2009). Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol, 35, 605-10.
  22. Plomgaard P, Nielsen AR, Fischer CP, et al (2007). Associations between insulin resistance and TNF-$\alpha$ in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia, 50, 2562-71.
  23. Qian YD, Xu X, Wang L, et al (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension. Asian Pac J Cancer Prev, 15, 9875-7.
  24. Shimura T, Kitagawa M, Yamada T, et al (2012). C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res, 32, 491-6.
  25. Tsounis D, Bouras G, Giannopoulos G, et al (2014). Inflammation markers in essential hypertension. Med Chem, 10, 672-81.
  26. Tosu AR, Demir S, Selcuk M, et al (2014). Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej, 10, 98-103.
  27. Wang G, Wang A, Tong W, et al (2011). Association of elevated inflammatory and endothelial biomarkers with prehypertension among Mongolians in China. Hypertens Res, 34, 516-20.
  28. White KL, Schildkraut JM, Palmieri RT, et al (2012). Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res, 72, 1064-9.
  29. Xiao Y, Liu J, Huang XE, et al (2014). Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pac J Cancer Prev, 15, 10445-9.
  30. Zhang S, Xu T, Peng Y, et al (2014). Combined action of C-reactive protein and lipid profiles on risk of hypertension and prehypertension in Mongolian adults in Inner Mongolia, China. Chin Med J, 127, 2016-20.
  31. Zhang J, Patel MB, Griffiths R, et al (2014). Tumor necrosis factor-$\alpha$ produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension, 64, 1275-81.